Close

Synageva Biopharma (GEVA) Misses Q4 EPS, Revenue Views

March 15, 2012 4:10 PM EDT
Synageva Biopharma (NASDAQ: GEVA) reported Q4 EPS of ($0.65), $0.27 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Synageva Biopharma (GEVA) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings